An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

NCT02596035 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

197

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb